articleThe Lancet OncologyApr 9, 2005Closed access

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

Ludwig Cancer Research · Instituto Brasileiro de Controle do Câncer · +19 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,579
total citations
FWCI
132.10
Percentile
100%
References
31
Citations per year

Authors

29

Topics & keywords

Keywords
  • Placebo
  • Medicine
  • Double blind
  • Virus-like particle
  • Human papillomavirus
  • Internal medicine
  • Virology
  • Recombinant DNA
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.